Blueprint Medicines Corp Research and Development Day with Q3 2019 Blueprint Medicines Corp Earnings Call Transcript
Okay, I think we'll get started here. I'm Jeff Albers. I am the CEO of Blueprint Medicines. And on behalf of all of our employees, I want to welcome those of you in the room here in New York City with us as well as those participating on the webcast.
Today marks an exceptional moment in time for us at Blueprint Medicines as we sit on the cusp of bringing our 2 lead programs, avapritinib and pralsetinib, directly to patients and with pending and planned regulatory filings in the near term. But with our long term strategy, it's truly grounded in transformational science and the discovery and development of new targets. And that's going to be our focus of our time together today.
And in that spirit, we have a lot to share. You're going to hear about 4 newly disclosed programs out of our pipeline. We're going to introduce you to our latest thinking on the number of patients with systemic mastocytosis, a number that could be 3 to 4x higher than what we've talked about or estimated previously. And then we're
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
